Mukhopadhyay Sandip, Niyogi Mausumi, Sarkar Joydip, Mukhopadhyay Basabdatta Samanta, Halder Swapan Kumar
Department of Pharmacology, Christian Medical College, Ludhiana, Punjab, India.
Department of Anaesthesiology, Burdwan Medical College, Burdwan, India.
J Anaesthesiol Clin Pharmacol. 2015 Apr-Jun;31(2):201-6. doi: 10.4103/0970-9185.155149.
In absence of any published standard guideline for sedation or anesthesia practice for prolonged therapeutic "endoscopic retrograde cholangio-pancreatography (ERCP)", safe and cost-effective sedation protocol is the need of the hour. Our study aims to evaluate the efficacy of a dexmedetomidine as an add-on for prolonged deep sedation for ERCP and to compare three deep sedation regimens regarding safety and efficacy.
Forty-five consecutively enrolled patients planned for therapeutic ERCP and assumed to have prolonged procedural duration (>50 min) were divided into three groups in a randomized assessor blinded fashion. Group 1 received propofol and midazolam, Group 2 received the sedato-analgesic cocktail containing ketamine-propofol-midazolam-pentazocine, and the Group 3 received sedate-analgesic cocktail plus dexmedetomidine infusion under monitoring of vital parameters and according to the judgment of the concerned anesthesiologist. Total propofol requirement, episodes of gagging, oxygen desaturation, changes in mean blood pressure (MBP), recovery and satisfaction score of endoscopist, anesthetist and patient were noted and analyzed statistically using one way ANOVA with Bonferroni correction and Chi-square test.
Mean propofol requirement, incidences of gagging and oxygen desaturation was significantly less in Group 2 and 3 compared to Group 1. MBP was more stable and recovery was faster in Group 3. Anesthetist's satisfaction was more with Group 2 and even more with Group 3.
The sedato-analgesic cocktail was superior to the conventional propofol-midazolam regimen, dexmedetomidine as add-on increased the efficacy and safety of sedate-analgesic cocktail. It reduces propofol requirement, helps to maintain the patient in a safe and more stable level of sedation and increases satisfaction of the anesthetist.
由于目前尚无已发表的关于延长治疗性“内镜逆行胰胆管造影术(ERCP)”镇静或麻醉操作的标准指南,因此当下需要安全且具成本效益的镇静方案。我们的研究旨在评估右美托咪定作为ERCP延长深度镇静辅助药物的疗效,并比较三种深度镇静方案的安全性和有效性。
连续纳入45例计划接受治疗性ERCP且预计操作时间延长(>50分钟)的患者,以随机、评估者盲法分为三组。第1组接受丙泊酚和咪达唑仑,第2组接受含有氯胺酮 - 丙泊酚 - 咪达唑仑 - 喷他佐辛的镇静镇痛合剂,第3组在生命体征参数监测下并根据相关麻醉医生的判断接受镇静镇痛合剂加右美托咪定输注。记录丙泊酚总需求量、呛咳发作次数、氧饱和度下降情况、平均血压(MBP)变化、内镜医师、麻醉医师和患者的恢复情况及满意度评分,并使用Bonferroni校正的单因素方差分析和卡方检验进行统计学分析。
与第1组相比,第2组和第3组的丙泊酚平均需求量、呛咳和氧饱和度下降发生率显著更低。第3组的MBP更稳定,恢复更快。麻醉医师对第2组的满意度更高,对第3组的满意度更高。
镇静镇痛合剂优于传统的丙泊酚 - 咪达唑仑方案;右美托咪定作为附加药物可提高镇静镇痛合剂的疗效和安全性。它减少了丙泊酚的需求量,有助于使患者维持在安全且更稳定的镇静水平,并提高麻醉医师的满意度。